Stragen New Molecules

Stragen is a Swiss-based pharmaceutical company that specializes in the development and commercialization of high-quality healthcare products, with a strong focus on women's health, critical care, and oncology. The company operates through two main pillars: a portfolio of complex generic medicines and a dedicated research division, often referred to as Stragen New Molecules, which focuses on innovative drug development. Their innovative pipeline includes advanced treatments for preterm labor and postpartum hemorrhage, leveraging specialized expertise in hormonal and peptide-based therapies. Stragen maintains a global presence, distributing its products in over 60 countries through a robust network of partners and subsidiaries.